FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Catherine Fiévet

Research Profile

Living Beings

Chemicals & Drugs

Disorders

Anatomy

Livers

Co-author Network

Publications

TOP 3
Josep Julve; Joan Carles Escolà-Gil; Noemi Rotllan; Catherine Fiévet; Emmanuelle Vallez; Carolina de la Torre; Vicent Ribas; John H Sloan; Francisco Blanco-Vaca
Human apolipoprotein A-II determines plasma triglycerides by regulating lipoprotein lipase activity and high-density lipoprotein proteome.
Fanny Lalloyer; Thomas Askov Pedersen; Barbara Gross; Sophie Lestavel; Saïd Yous; Emmanuelle Vallez; Jan-Ake Gustafsson; Susanne Mandrup; Catherine Fiévet; Bart Staels; Anne Tailleux
Rexinoid bexarotene modulates triglyceride but not cholesterol metabolism via gene-specific permissivity of the RXR/LXR heterodimer in the liver.
Catherine Fiévet; Bart Staels
Liver X receptor modulators: effects on lipid metabolism and potential use in the treatment of atherosclerosis.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Catherine Fiévet (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2010: Josep Julve; Joan Carles Escolà-Gil; Noemi Rotllan; Catherine Fiévet; Emmanuelle Vallez; Carolina de la Torre; Vicent Ribas; John H Sloan; Francisco Blanco-Vaca
Human apolipoprotein A-II determines plasma triglycerides by regulating lipoprotein lipase activity and high-density lipoprotein proteome.
Arteriosclerosis, thrombosis, and vascular biology 2010;30(2):232-8.
2009: Fanny Lalloyer; Thomas Askov Pedersen; Barbara Gross; Sophie Lestavel; Saïd Yous; Emmanuelle Vallez; Jan-Ake Gustafsson; Susanne Mandrup; Catherine Fiévet; Bart Staels; Anne Tailleux
Rexinoid bexarotene modulates triglyceride but not cholesterol metabolism via gene-specific permissivity of the RXR/LXR heterodimer in the liver.
Arteriosclerosis, thrombosis, and vascular biology 2009;29(10):1488-95.
2009: Catherine Fiévet; Bart Staels
Liver X receptor modulators: effects on lipid metabolism and potential use in the treatment of atherosclerosis.
Biochemical pharmacology 2009;77(8):1316-27.
2008: Laura Calpe-Berdiel; Noemí Rotllan; Catherine Fiévet; Rosa Roig; Francisco Blanco-Vaca; Joan Carles Escolà-Gil
Liver X receptor-mediated activation of reverse cholesterol transport from macrophages to feces in vivo requires ABCG5/G8.
Journal of lipid research 2008;49(9):1904-11.
2008: Roxane M Mansouri; Eric Baugé; Philippe Gervois; Jamila Fruchart-Najib; Catherine Fiévet; Bart Staels; Jean-Charles Fruchart
Atheroprotective effect of human apolipoprotein A5 in a mouse model of mixed dyslipidemia.
Circulation research 2008;103(5):450-3.
2006: Fanny Lalloyer; Catherine Fiévet; Sophie Lestavel; Gérard Torpier; Jelske van der Veen; Véronique Touche; Stéphanie Bultel; Saïd Yous; Folkert Kuipers; Réjane Paumelle; Jean-Charles Fruchart; Bart Staels; Anne Tailleux
The RXR agonist bexarotene improves cholesterol homeostasis and inhibits atherosclerosis progression in a mouse model of mixed dyslipidemia.
Arteriosclerosis, thrombosis, and vascular biology 2006;26(12):2731-7.
2006: Catherine Fiévet; Jean-Charles Fruchart; Bart Staels
PPARalpha and PPARgamma dual agonists for the treatment of type 2 diabetes and the metabolic syndrome.
Current opinion in pharmacology 2006;6(6):606-14.
2006: Fanny Lalloyer; Brigitte Vandewalle; Frédéric Percevault; Gérard Torpier; Julie Kerr Conte; Maaike Oosterveer; Réjane Paumelle; Jean-Charles Fruchart; Folkert Kuipers; François Pattou; Catherine Fiévet; Bart Staels
Peroxisome proliferator-activated receptor alpha improves pancreatic adaptation to insulin resistance in obese mice and reduces lipotoxicity in human islets.
Diabetes 2006;55(6):1605-13.
2005: Anne Tailleux; Andrea Gozzo; Gérard Torpier; Françoise Martin-Nizard; Dominique Bonnefont-Rousselot; Mohamed Lemdani; Christophe Furman; Rachel Foricher; Gwénaël Chevé; Saïd Yous; Florence Micard; Régis Bordet; Monique Gardes-Albert; Daniel Lesieur; Elisabeth Teissier; Jean-Charles Fruchart; Catherine Fiévet; Patrick Duriez
Increased susceptibility of low-density lipoprotein to ex vivo oxidation in mice transgenic for human apolipoprotein B treated with 1 melatonin-related compound is not associated with atherosclerosis progression.
Journal of cardiovascular pharmacology 2005;46(3):241-9.
2005: Nathalie Hennuyer; Anne Tailleux; Gérard Torpier; Hafid Mezdour; Jean-Charles Fruchart; Bart Staels; Catherine Fiévet
PPARalpha, but not PPARgamma, activators decrease macrophage-laden atherosclerotic lesions in a nondiabetic mouse model of mixed dyslipidemia.
Arteriosclerosis, thrombosis, and vascular biology 2005;25(9):1897-902.
2005: Hélène Duez; Bruno Lefebvre; Philippe Poulain; Inés Pineda Torra; Frédéric Percevault; Gérald Luc; Jeffrey M Peters; Frank J Gonzalez; Romain Gineste; Stéphane Helleboid; Vladimir Dzavik; Jean-Charles Fruchart; Catherine Fiévet; Philippe Lefebvre; Bart Staels
Regulation of human apoA-I by gemfibrozil and fenofibrate through selective peroxisome proliferator-activated receptor alpha modulation.
Arteriosclerosis, thrombosis, and vascular biology 2005;25(3):585-91.
2004: Rima Elhage; Pierre Gourdy; Laurent Brouchet; Jacek Jawien; Marie-José Fouque; Catherine Fiévet; Xavier Huc; Yara Barreira; Jean Claude Couloumiers; Jean-François Arnal; Francis Bayard
Deleting TCR alpha beta+ or CD4+ T lymphocytes leads to opposite effects on site-specific atherosclerosis in female apolipoprotein E-deficient mice.
The American journal of pathology 2004;165(6):2013-8.
2003: Anne Tailleux; Gérard Torpier; Hafid Mezdour; Jean-Charles Fruchart; Bart Staels; Catherine Fiévet
Murine models to investigate pharmacological compounds acting as ligands of PPARs in dyslipidemia and atherosclerosis.
Trends in pharmacological sciences 2003;24(10):530-4.
2002: Hélène Duez; Yu-Sheng Chao; Melba Hernandez; Gérard Torpier; Philippe Poulain; Steven S Mundt; Ziad Mallat; Elisabeth Teissier; Charlotte A Burton; Alain Tedgui; Jean-Charles Fruchart; Catherine Fiévet; Samuel D Wright; Bart Staels
Reduction of atherosclerosis by the peroxisome proliferator-activated receptor alpha agonist fenofibrate in mice.
The Journal of biological chemistry 2002;277(50):48051-7.
2002: Eric Raspé; Hélène Duez; Anethe Mansén; Coralie Fontaine; Catherine Fiévet; Jean-Charles Fruchart; Björn Vennström; Bart Staels
Identification of Rev-erbalpha as a physiological repressor of apoC-III gene transcription.
Journal of lipid research 2002;43(12):2172-9.
2001: Nicholas M Morton; Megan C Holmes; Catherine Fiévet; Bart Staels; Anne Tailleux; John J Mullins; Jonathan R Seckl
Improved lipid and lipoprotein profile, hepatic insulin sensitivity, and glucose tolerance in 11beta-hydroxysteroid dehydrogenase type 1 null mice.
The Journal of biological chemistry 2001;276(44):41293-300.
2001: T Claudel; Mark D Leibowitz; Catherine Fiévet; Anne Tailleux; B Wagner; Joyce J Repa; Gérard Torpier; Jean-Marc Lobaccaro; James R Paterniti; D J Mangelsdorf; Richard A Heyman; Johan Auwerx
Reduction of atherosclerosis in apolipoprotein E knockout mice by activation of the retinoid X receptor.
Proceedings of the National Academy of Sciences of the United States of America 2001;98(5):2610-5.
2001: Eric Raspé; Hélène Duez; Philippe Gervois; Catherine Fiévet; Jean-Charles Fruchart; Sandrine Besnard; Jean Mariani; Alain Tedgui; Bart Staels
Transcriptional regulation of apolipoprotein C-III gene expression by the orphan nuclear receptor RORalpha.
The Journal of biological chemistry 2001;276(4):2865-71.
2000: Anne Tailleux; Muriel Bouly; Gérald Luc; Graciela Castro; Jean-Michel Caillaud; Nathalie Hennuyer; Philippe Poulain; Jean-Charles Fruchart; Nicolas Duverger; Catherine Fiévet
Decreased susceptibility to diet-induced atherosclerosis in human apolipoprotein A-II transgenic mice.
Arteriosclerosis, thrombosis, and vascular biology 2000;20(11):2453-8.
2000: Mark D Leibowitz; Catherine Fiévet; Nathalie Hennuyer; Julia Peinado-Onsurbe; Hélène Duez; J Bergera; C A Cullinan; Carl P Sparrow; Joanne Baffic; G D Berger; C Santini; R W Marquis; Richard L Tolman; Roy G Smith; David E Moller; Johan Auwerx
Activation of PPARdelta alters lipid metabolism in db/db mice.
FEBS letters 2000;473(3):333-6.
1999: K Schoonjans; Julia Peinado-Onsurbe; Jean-Charles Fruchart; Anne Tailleux; Catherine Fiévet; Johan Auwerx
3-Hydroxy-3-methylglutaryl CoA reductase inhibitors reduce serum triglyceride levels through modulation of apolipoprotein C-III and lipoprotein lipase.
FEBS letters 1999;452(3):160-4.
1999: Nathalie Hennuyer; Philippe Poulain; Lise Madsen; R K Berge; L M Houdebine; Didier Branellec; Jean-Charles Fruchart; Catherine Fiévet; Nicolas Duverger; Bart Staels
Beneficial effects of fibrates on apolipoprotein A-I metabolism occur independently of any peroxisome proliferative response.
Circulation 1999;99(18):2445-51.
1997: Rima Elhage; Francis Bayard; Vincent RICHARD; P Holvoet; Nicolas Duverger; Catherine Fiévet; Jean-François Arnal
Prevention of fatty streak formation of 17beta-estradiol is not mediated by the production of nitric oxide in apolipoprotein E-deficient mice.
Circulation 1997;96(9):3048-52.
1997: B Igau; Graciela Castro; Véronique Clavey; C Slomianny; R Bresson; P Drouin; J C Fruchart; Catherine Fiévet
In vivo glucosylated LpA-I subfraction. Evidence for structural and functional alterations.
Arteriosclerosis, thrombosis, and vascular biology 1997;17(11):2830-6.
1997: Rima Elhage; Jean-François Arnal; MT Pieraggi; Nicolas Duverger; Catherine Fiévet; Jean-Charles Faye; Francis Bayard
17 beta-estradiol prevents fatty streak formation in apolipoprotein E-deficient mice.
Arteriosclerosis, thrombosis, and vascular biology 1997;17(11):2679-84.
1997: C Decossin; Graciela Castro; B Derudas; M Bertrand; J C Fruchart; Catherine Fiévet
Subclasses of LpA-I in coronary artery disease: distribution and cholesterol efflux ability.
European journal of clinical investigation 1997;27(4):299-307.
1996: Olivier Ziegler; L Méjean; B Igau; Jean-Charles Fruchart; Pierre Drouin; Catherine Fiévet
Accessibility of human apolipoprotein B-100 epitopes in insulin-dependent diabetes: relation with the surface lipid environment of atherogenic particles.
Diabetes & metabolism 1996;22(3):179-84.
1996: B Igau; Sophie Lestavel; Véronique Clavey; C Slomianny; Pierre Drouin; R Bresson; Jean-Charles Fruchart; Patrick Duriez; Catherine Fiévet
Apo B-containing lipoprotein particles in poorly controlled insulin-dependent diabetes.
Atherosclerosis 1996;120(1-2):209-19.
1995: Catherine Fiévet; B Igau; R Bresson; Pierre Drouin; Jean-Charles Fruchart
Non-enzymatic glycosylation of apolipoprotein A-I and its functional consequences.
Diabète & métabolisme 1995;21(2):95-8.
1995: C Decossin; A Tailleux; Jean-Charles Fruchart; Catherine Fiévet
Prevention of in vitro low-density lipoprotein oxidation by an albumin-containing Lp A-I subfraction.
Biochimica et biophysica acta 1995;1255(1):31-8.
1994: E Campos; P Fiévet; E Cacès; Jean-Charles Fruchart; Catherine Fiévet
A screening method for abnormally high lipoprotein(a) concentrations by agarose lipoprotein electrophoresis.
Clinica chimica acta; international journal of clinical chemistry 1994;230(1):43-50.